Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma

British Journal of Haematology

Volumn 121, Issue 1, 2003, Pages 44-48

  Pettengell, Ruth ^a   Linch, David ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Aggressive non Hodgkin's lymphoma; Diffuse large B cell lymphoma; Monoclonal antibody therapy; Rituximab

Indexed keywords

CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUOXYMESTERONE; HYDROXYDAUNORUBICIN; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYSPNEA; EDEMA; FATIGUE; FEVER; FLUSHING; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPOTENSION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RASH; RHINITIS; RIGOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG COSTS; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; PREDNISONE; RECURRENCE; VINCRISTINE;

EID: 0037394103     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04274.x     Document Type: Article

References (28)

1. Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. & Shen, D. (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 995-1001.
2. Bruno, G., Ballester, O., Willcox, P., Fang, T., Payne, M. & Tan, B. (2000) MIDET + rituximab is an effective regimen for poor prognosis non-Hodgkin's lymphoma patients receiving high dose therapy. Blood, 96, 796a.
3. Buckstein, R., Imrie, K., Spaner, D., Potichny, A., Robinson, J.B., Nanji, S., Pennel, N., Reis, M., Pinkerton, P., Dube, I., Hewitt, K. & Berinstein, N.L. (1999) Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low grade non-Hodgkin's lymphoma. Seminars in Oncology, 26, 115-122.
4. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V. & Reyes, F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: multicenter phase II study. Blood, 92, 1927-1932.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL). New England Journal of Medicine, 346, 235-242.
6. Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. & Varns, C. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal anti-body and CHOP chemotherapy. Journal of Clinical Oncology, 17, 268-276.
7. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. & Bonavida, B. (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy and Radiopharmacology, 12, 177-186.
8. Dixon, D.O., Neilan, B., Jones, S.E., Lipschitz, D.A., Miller, T.P., Grozea, P.N. & Wilson, H.E. (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. Journal of Clinical Oncology, 4, 295-305.
9. Elias, L., Portlock, C.S. & Rosenberg, S.A. (1978) Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer, 42, 1705-1710.
10. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, Jr. C.A. & Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
11. Ghetie, M.A., Bright, H. & Vitetta, E.S. (2001) Homodimers but not monomers of rituximab (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 97, 1392-1398.
12. Gutierrez, M., Chabner, B.A., Pearson, D., Steinberg, S.M., Jaffe, E.S., Cheson, B.D., Fojo, A. & Wilson, W.H. (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8 year follow-up study of EPOCH. Journal of Clinical Oncology, 18, 3633-3642.
13. Hamblin, T., Bes, J.H., Hornberger, J. & Morris, J. (2002) Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma. British Journal of Haematology. 117, 59, a170.
14. Hess, G.R., Flohr, T., Kolbe, K., Huber, Ch. & Derigs, H.-G. (2001) High Dose Therapy Combined with Rituximab in Patients with Relapsed B-NHL After in Vitro and in Vivo Purging. Montreaux, Switzerland.
15. Jost, L.M., Jermann, M., Stahel, R.A., Honegger, H., Kroner, T. & Egli, F. (2001) Rituximab-EPOCH: an effective salvage regimen for relapsed, refractory or transformed B-cell lymphoma. Results of a phase II study. ASCO, 20, 290a.
16. Kewalramani, T., Zelenetz, A., Bertino, J., Donnelly, G., Hedrick, E., Noy, A., O'Connor, O., Portlock, C., Straus, D., Yahalom, J., Gencarelli, A., Remy, D., Qin, J., Nimer, S. & Moskowitz, C. (2001) Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood, 98, 346a.
17. Magni, M., Di Nicola, M., Devizzi, L., Matteucci, P., Lombardi, F., Gandola, L., Ravagnani, F., Giardini, R., Dastoli, G., Tarella, C., Pileri, A., Bonadonna, G. & Gianni, A.M. (2000) Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 96, 864-869.
18. Maloney, D., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. & Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-CSB8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457-2466.
19. Maloney, D., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
20. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y. & Harousseau, J.L. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540-1545.
21. Piro, L.D., White, C.A., Grillo-Lopez, A.J., Janakiraman, N., Saven, A., Beck, T.M., Varns, C., Shuey, S., Czuczman, M., Lynch, J.W., Kolitz, J.E. & Jain, V. (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 10, 655-661.
22. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 84, 2457-2466.
23. Santini, G., Salvagno, L., Leoni, P., Chisesi, T., De Souza, C., Sertoli, M.R., Rubagotti, A., Congiu, A.M., Centurioni, R., Olivieri, A., Tedeschi, L., Vespignani, M., Nati, S., Soracco, M., Porcellini, A., Contu, A., Guarnaccia, C., Pescosta, N., Majolino, I., Spriano, M., Vimercati, R., Rossi, E., Zambaldi, G., Mangoni, L., Endrizzi, L., Sileni, V.C., Miggiano, M.C., Marino, G., Damasio, E. & Rizzoli, V. (1998) VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology, 16, 2796-2802.
24. Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G.P., Coiffier, B., Connors, J.M., Cowan, R.A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R.I., Gisselbrecht, C., Horning, S.J., Lepage, E., Lister, T.A., Meerwaldt, J.H., Montserrat, E., Nissen, N.I., Oken, M.M., Peterson, B.A., Tondini, C., Velasquez, W.A. & Yeap, B.Y. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987-994.
25. Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., van Reijswoud, I., Hop, W. & Lowenberg, B. (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Journal of Clinical Oncology. 13, 2530-2539.
26. Tarella, C., Ladetto, M., Boccadoro, M., Cuttica, A., Vallet, S., Gallamini, A., Pescarollo, A., Patti, C., Coser, P., Zoli, V., Magni, M. & Gianni, A.M. (2001) High Dose Sequential Chemotherapy with PBPC Autografting Supplemented with Rituximab in IPI 2-3 B-Cell Diffuse Large Cell Lymphoma. Montreaux, Switzerland.
27. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T., Gisselbrecht, C. & Reyes, F. (2000) A randomised comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: The LNH93-5. Blood, 96, 832a.
28. Vose, J.M., Link, B.K., Grossbard, M.L., Czuczman, M., Grillo-Lopez, A., Gilman, P., Lowe, A., Kunkel, L.A. & Fisher, R.I. (2001) Chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 19, 389-397.